REVIEWIs there a role for secondary debulking in ovarian cancer? A review of the current literatureKrause, Danielle; Richardson, Debra L. Author Information Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Correspondence to Debra L. Richardson, MD, Section Chief, Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 800 NE 10th Street, Oklahoma City, OK 73104, USA. Tel: +1 405 271 8001; e-mail: [email protected] Current Opinion in Obstetrics and Gynecology: October 14, 2022 - Volume - Issue - 10.1097/GCO.0000000000000831 doi: 10.1097/GCO.0000000000000831 Buy PAP Metrics Abstract Purpose of review Until recently, no data was available from randomized, controlled trials (RCT) to assess the role of secondary cytoreductive surgery (CRS) in the management of recurrent epithelial ovarian cancer. This review highlights results from the three completed RCTs, and other recent literature on this topic. Recent findings Both the AGO and iMODEL criteria predict high rates of complete gross resection at the time of secondary CRS. Overall survival (OS) was improved in the surgical arms in both DESKTOP 3 and SOC-1. In contrast, surgery did not improve OS in GOG 213, but greater than 80% of patients received bevacizumab with chemotherapy in GOG 213. Summary Secondary cytoreduction for recurrent ovarian cancer can be considered in patients who meet specific criteria. Available data supports improvement in OS for patients not receiving bevacizumab, who achieve complete gross resection. Surgery is harmful to patients with gross residual disease. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.